Targeting Tumour-Initiating Cells with TRAIL Based Combination Therapy Ensures Complete and Lasting Eradication of Multiple Myeloma Tumours In Vivo
Figure 2
In vitro sensitivity of CD138+ RPMI8226 cells to TRAIL alone, or TRAIL after pre-incubation with DOX.
Following immunomagnetic separation, CD138+ cells (1×105 /ml) were incubated with increasing concentrations of TRAIL alone (5, 10 and 25 ng/ml) for 24 h (black bars), or TRAIL for 24 h after initial pre-incubation with DOX (500 ng/ml) for 6, 12 or 24 h (white bars). Cytotoxicity was measured by MTS assay and expressed as a percentage of the untreated control sample. For details see Materials and Methods. Data represent the mean ±1SD of the three independent experiments.